ImmunoForge Co., Ltd., a biopharmaceutical company developing treatments for rare diseases, announced that they will participate in Bio-Europe Spring 2026, held in Lisbon, Portugal, from March 23rd to ...

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to ...

Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...

Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline. These include, among others, monlunabant (phase 2); oral and subcutaneous ...

The first time that University of Oxford astronomer Lyla Jung saw the cosmic configuration on her monitor, she almost didn’t believe it was real. But it was—and Jung and her colleagues went on to ...

Long gone are the days of ‘one size fits all’ hair products, and whether you have an afro texture or poker-straight hair, ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Health influencers promise an astonishing range of benefits from peptides, almost none of them tested in humans ...

The benefits of peptide moisturisers, why you should try it and the key benefits of using a peptide moisturiser, according to ...

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS ...